Endothelial cells and macrophages, partners in atherosclerotic plaque progression

Archives of Physiology and Biochemistry

Volumn 112, Issue 4-5, 2006, Pages 245-253

  Antohe, Felicia ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

2D electrophoresis; Atherosclerosis; Endothelial cell; Folic acid; Macrophage

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL POPULATION; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE MARKER; ENDOCYTOSIS; ENDOTHELIUM CELL; FOAM CELL; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; INTRAVASCULAR ULTRASOUND; MACROPHAGE; MICROENVIRONMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T LYMPHOCYTE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR SYSTEM; CARRIER PROTEINS; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENDOTHELIAL CELLS; FLUORESCENT DYES; FOAM CELLS; FOLIC ACID; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; PERIPHERAL VASCULAR DISEASES; PROTEOME; RECEPTORS, CELL SURFACE; RISK FACTORS;

EID: 33845905195     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450601094706     Document Type: Review

References (64)

1. Ala-Korpela M, Sipola P, Kaski K. 2006. Characterization and molecular detection of atherothrombosis by magnetic resonance-potential tools for individual risk assessment and diagnostics. Ann Med 38(5):322-36.
2. Almofti MR, Huang Z, Yang P, Rui Y, Yang P. 2006. Proteomic analysis of rat aorta during atherosclerosis induced by high cholesterol diet and injection of vitamin D3. Clin Exp Pharmacol Physiol 33(4):305-9.
3. Antohe F, Radulescu L, Puchianu E, Kennedy MD, Low PS, Simionescu M. 2005a. Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia. Cell Tissue Res 320:277-85.
4. Antohe F, Radulescu L, Puchianu E, Kennedy MD, Low PS, Simionescu M. 2005b. Over-expression of folate receptors in activated macrophages in experimental hyperlipemia; a potential tool for drug targeting. 8th International Conferences Vascular Endothelium: Translating Discoveries into Public Health Practice; 2005 June 25 - July 2, Knossos Royal Village, Crete, Greece. p 59.
5. Antohe F, Radulescu L, Uyy E, Low PS, Simionescu M. 2006. Folate receptors and proteomic analysis of endothelial cells in atherosclerosis. XIV International Symposium on Atherosclerosis; 2006 June 18 - 22; Rome, Italy; Elsevier. p 590.
6. Antony AC. 1996. Folate receptors. Annu Rev Nutr 16:501-21.
7. Berhane BT, Zong C, Liem DA, Huang A, Le S, Edmondson RD, Jones RC, Qiao X, Whitelegge JP, Ping P, Vondriska TM. 2005. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 5(13):3520-30.
8. Blankenberg FG, Mari C, Strauss HW. 2002. Development of radiocontrast agents for vascular imaging: progress to date. Am J Cardiovasc Drugs 2(6):357-65. Review.
9. Brown MS, Goldstein JL. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-61.
10. Brueckmann M, Bertsch T, Lang S, Sueselbeck T, Wolpert C, Kaden JJ, Jaramillo C, Huhle G, Borggrete M, Haase KK. 2004. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clin Chem Lab Med 42:1132-9.
11. Bruneel A, Labas V, Mailloux A, Sharma S, Royer N, Vinh J, Pernet P, Vaubourdolle M, Baudin B. 2005. Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 5(15):3876-84.
12. Duran MC, Mas S, Martin-Ventura JL, Meilhac O, Michel JB, Gallego-Delgado J, Lazaro A, Tunon J, Egido J, Vivanco F. 2003. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics 3(6):973-8.
13. Edgell CJ, McDonald CC, Graham JB. 1983. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80(12):3734-7.
14. Falk E. 2006. Pathogenesis of atherosclerosis. J Am Coll Cardiol 47(8 Suppl):C7-12.
15. Fogelman AM, Scechter I, Seager J, Hokom M, Child JS, Edwards PA. 1980. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 77:2214-8.
16. Franzen B, Duvefelt K, Jonsson C, Engelhardt B, Ottervald J, Wickman M, Yang Y, Schuppe-Koistinen I. 2003. Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res 115(2):130-46.
17. Gallego-Delgado J, Lazaro A, Osende JI, Barderas MG, Blanco-Colio LM, Duran MC, Martin-Ventura JL, Vivanco F, Egido J. 2005. Proteomic approach in the search of new cardiovascular biomarkers. Kidney Int Suppl (99):S103-7.
18. Glass CK, Witztum JL. 2001. Atherosclerosis. The road ahead. Cell 104(4):503-16.
19. Hajjar DP, Haberland ME. 1997. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 272(37):22975-8.
20. Hamilton TA, Major JA, Chisolm GM. 1995. The effects of oxidized low density lipoproteins on inducible mouse macrophage gene expression are gene and stimulus dependent. J Clin Invest 95(5):2020-7.
21. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, Quehenberger O. 2000. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest 106(6):793-802.
22. Holvoet P, Harris TB, Tracy RP, et al. 2003. Association of high coronary heart disease risk status with circulating oxidized LDL in the well functioning elderly. Arterioscler Throb Vasc Biol 23:1444-8.
23. Holvoet P, Vanhaecke J, Janssens S, et al. 1998. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-94.
24. Kamen BA, Smith AK, Anderson RG. 1991. The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest 87:1442-9.
25. Karsan A, Blonder J, Law J, Yaquian E, Lucas DA, Conrads TP, Veenstra T. 2005. Proteomic analysis of lipid microdomains from lipopolysaccharide-activated human endothelial cells. J Proteome Res 4(2):349-57.
26. Lawn RM, Wade DP, Couse TL, Wilcox JN. 2001. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 21(3):378-85.
27. Leamon CP, Low PS. 1991. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 88:5572-6.
28. Lee RJ, Low PS. 1994. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-204.
29. Libby P. 2000. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Is J Cardiol 86(8B):3J-8J.
30. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-74.
31. Libby P. 2006. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006 Feb;83(2):456S-460S. Review.
32. Liu Y, Hulten LM, Wiklund O. 1997. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol 17(2):317-23.
33. Lu Y, Low PS. 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54(5):675-93.
34. Lu Y, Sega E, Leamon CP, Low PS. 2004. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 56(8):1161-76.
35. Lusis A. 2000. Atherosclerosis. Nature 407(6801):233-41.
36. Ma ZC, Gao Y, Wang J, Zhang XM, Wang SQ. 2006. Proteomic analysis effects of ginsenoside Rg1 on human umbilical vein endothelial cells stimulated by tumor necrosis factor-alpha. Life Sci 79(2):175-81.
37. Mayr M, Mayr U, Chung YL, Yin X, Griffiths JR, Xu Q. 2004. Vascular proteomics: linking proteomic and metabolomic changes. Proteomics 4(12):3751-61.
38. Mayr M, Chung YL, Mayr U, Yin X, Ly L, Troy H, Fredericks S, Hu Y, Griffiths JR, Xu Q. 2005. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 25(10):2135-42.
39. Mayr M, Zhang J, Greene AS, Gutterman DD, Perloff JK, Ping P. 2006. Proteomic based development of biomarkers in cardiovascular disease: Mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics May 29; [Epub ahead of print].
40. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratman M, Matsuyama T. 1999. Selective expression of folate receptor beta and its possible role in methotrexane transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42:1609-16.
41. Nicholls SJ, Sipahi I. 2006. Emerging role of intravascular ultrasound in the assessment of experimental ant-atherosclerotic therapies. Curr Med Chem 13(15):1727-34.
42. Osiecki H. 2004. The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev 9(1):32-53. Review.
43. Paulos CM, Turk MJ, Breur GJ, Low PS. 2004. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56(8):1205-17.
44. Radulescu L, Manduteanu I, Antohe F, Simionescu M. 2003. Detection of new antigens in activated endothelial cells by high-resolution 2-D gel technology. Bio-Rad Electrophoresis-Tech Note 2979:1-6.
45. Radulescu L, Stancu C, Antohe F. 2004. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins. Med Sci Monit 10:BR 207-14.
46. Reddy JA, Allagadda VM, Leamon CP. 2005. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol 6(2):131-50.
47. Roos RN. 1999. Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-26.
48. Sailer J, Rand T, Berg A, Sulzbacher I, Peloschek P, Holzenbein T, Lammer J. 2006. High-resolution 3 T MR microscopy imaging of arterial walls. Cardiovasc Intervent Radiol 2006 Sep-Oct;29(5):771-7.
49. Salter DN, Scott H, Slade H, Andrews P. 1981. The preparation and properties of folate-binding protein from cow's milk. Biochem J 193:469-76.
50. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. 2004. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol 287(2):C517-26.
51. Selhub J, Ahmad O, Rosenberg IH. 1980. Preparation and use of affinity columns with bovine milk folate-binding protein (FBP) covalently linked to Sepharose 4B. Methods Enzymol 66:686-90.
52. Shastry S, Tyagi N, Hayden MR, Tyagi SC. 2004. Proteomic analysis of homocysteine inhibition of microvascular endothelial cell angiogenesis. Cell Mol Biol (Noisy-le-grand) 50(8):931-7.
53. Shiffman D, Mikita T, Tai JT, Wade DP, Porter JG, Seilhamer JJ, Somogyi R, Liang S, Lawn RM. 2000. Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem 275(48):37324-32.
54. Simionescu M, Antohe F. 2006. Functional ultrastructure of the vascular endothelium-changes in various pathologies. In: Salvador M, Annie H, editors, The vascular endothelium. Berlin-Heidelberg-New York: Springer-Verlag.
55. Simionescu N, Mora R, Vasile E, Lupu F, Filip D, Simionescu M. 1990. Prelesional modifications of vessel wall in hyperlipidemic atherogenesis. Extracellular accumulation of modified and reassembled lipoproteins. Ann NY Acad Sci 598:1-16.
56. Simionescu N, Simionescu M. 1991. Cellular interactions of lipoproteins with the vascular endothelium: endocytosis and transcytosis. Targeted Diagn Ther 5:45-95.
57. Sudimack J, Lee RJ. 2000. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41(2):147-62.
58. Sung HJ, Ryang YS, Jang SW, Lee CW, Han KH, Ko J. 2006. Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers 11(3):279-90.
59. Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL, Palinski W, Tsimikas S. 2004. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 24(12):2307-12. Epub 2004 Nov 4.
60. Tuomisto TT, Binder BR, Yla-Herttuala S. 2005. Genetics, genomics and proteomics in atherosclerosis research. Ann Med 37(5):323-32.
61. Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, Low PS. 2002. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis & Rheumatism 46:1947-55.
62. Vaarala O. 2000. Auto-antibodies to modified LDLs and other phospholipids-protein complexes as markers of cardiovascular diseases. J Int Med 247:381-4.
63. Wang X, Reape TJ, Li X, Rayner K, Webb CL, Burnand KG, Lysko PG. 1999. Induced expression of adipophilin mRNA in human macrophages stimulated with oxidized low-density lipoprotein and in atherosclerotic lesions. FEBS Lett 462(1-2):145-50.
64. Wellnhofer E, Goubergrits L, Kertzscher U, Affeld K. 2006. In-vivo coronary flow profiling based on biplane angiograms: influence of geometric simplifications on the three-dimensional reconstruction and wall shear stress calculation. Biomed Eng Online 14;5:39.